A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis

9Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Background LEO 43204 is a novel ingenol derivative in development for the treatment of actinic keratosis. Objectives To compare the safety and preliminary efficacy of three doses of LEO 43204 with ingenol mebutate in actinic keratoses (AKs). Methods Patients with at least three visible, discrete, nonkeratotic AKs on four separate selected treatment areas on the forearms received LEO 43204 gel (0·025%, 0·05% and 0·075%) and ingenol mebutate 0·05% gel, by investigator-blinded, randomized allocation, for 2 consecutive days. Patients were assessed at 8 weeks. Primary outcomes included maximum composite local skin response (LSR) score and adverse events (AEs). Secondary outcomes included a reduction in the number of visible AKs. Results Forty patients completed the trial. For all treatments, mean LSR scores peaked at week 1, and were below baseline by week 8. Mean maximum composite LSR scores for LEO 43204 0·025%, 0·05% and 0·075% were 9·2 (Dunnett adjusted P = 0·02), 10·1 (Dunnett adjusted P = 0·90) and 11·2 (Dunnett adjusted P < 0·01), respectively, vs. ingenol mebutate 0·05% gel (10·0). The most frequent AEs across all treatments were application site pruritus, burning sensation and tenderness. Mean reduction in the number of AKs was comparable for ingenol mebutate and the two lowest doses of LEO 43204 (71·9-73·1%), but LEO 43204 0·075% gave a significantly larger reduction (81·8%; Dunnett adjusted P = 0·04). Conclusions LEO 43204 had a similar safety profile to ingenol mebutate and a dose-response relationship for LSRs was demonstrated. The highest LEO 43204 dose (0·075%) significantly reduced the AK count when compared with ingenol mebutate.

References Powered by Scopus

Ingenol mebutate gel for actinic keratosis

420Citations
N/AReaders
Get full text

The natural history of actinic keratosis: A systematic review

290Citations
N/AReaders
Get full text

The actinic (solar) keratosis: A 21st-century perspective

158Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Actinic keratosis and cutaneous squamous cell carcinoma - Treatment options

36Citations
N/AReaders
Get full text

Anti-acne drugs in phase 1 and 2 clinical trials

32Citations
N/AReaders
Get full text

Ingenol Disoxate: A Novel 4-Isoxazolecarboxylate Ester of Ingenol with Improved Properties for Treatment of Actinic Keratosis and Other Non-Melanoma Skin Cancers

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sinnya, S., Tan, J. M., Prow, T. W., Primiero, C., McEniery, E., Selmer, J., … Soyer, H. P. (2016). A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis. British Journal of Dermatology, 174(2), 305–311. https://doi.org/10.1111/bjd.14245

Readers' Seniority

Tooltip

Professor / Associate Prof. 3

50%

Lecturer / Post doc 1

17%

PhD / Post grad / Masters / Doc 1

17%

Researcher 1

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

78%

Biochemistry, Genetics and Molecular Bi... 1

11%

Pharmacology, Toxicology and Pharmaceut... 1

11%

Save time finding and organizing research with Mendeley

Sign up for free